Detalhe da pesquisa
1.
Efficacy and safety of the glucagon receptor antagonist PF-06291874: A 12-week, randomized, dose-response study in patients with type 2 diabetes mellitus on background metformin therapy.
Diabetes Obes Metab
; 20(11): 2608-2616, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29923286
2.
Investigation of pharmacokinetic drug interaction between clesacostat and DGAT2 inhibitor ervogastat in healthy adult participants.
Clin Transl Sci
; 17(2): e13687, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38362827
3.
Metabolism and Excretion of Nirmatrelvir in Humans Using Quantitative Fluorine Nuclear Magnetic Resonance Spectroscopy: A Novel Approach for Accelerating Drug Development.
Clin Pharmacol Ther
; 112(6): 1201-1206, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35678736
4.
Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males.
Br J Clin Pharmacol
; 71(3): 429-36, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21284702
5.
Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: A randomized phase 2 trial.
Med
; 2(7): 800-813.e3, 2021 07 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35590219
6.
Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans.
Drug Metab Dispos
; 38(3): 474-83, 2010 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-20016053
7.
Mini-Review: Comprehensive Drug Disposition Knowledge Generated in the Modern Human Radiolabeled ADME Study.
CPT Pharmacometrics Syst Pharmacol
; 9(8): 428-434, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32562380
8.
Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers.
J Clin Pharmacol
; 49(1): 80-7, 2009 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19004846
9.
A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects.
J Clin Pharmacol
; 49(8): 937-46, 2009 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-19602719
10.
Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
Br J Clin Pharmacol
; 68(4): 535-45, 2009 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-19843057
11.
Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies.
Lancet
; 370(9603): 1907-14, 2007 Dec 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-18068514
12.
Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects.
Br J Clin Pharmacol
; 66(1): 36-42, 2008 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-18503607
13.
Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects.
J Clin Pharmacol
; 47(2): 159-64, 2007 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-17244766
14.
Effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjects.
J Clin Pharmacol
; 46(3): 321-7, 2006 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-16490808
15.
Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients.
J Clin Pharmacol
; 46(3): 328-36, 2006 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-16490809
16.
Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers.
J Clin Pharmacol
; 46(3): 291-300, 2006 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-16490805
17.
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Clin Ther
; 28(1): 55-72, 2006 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-16490580
18.
Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions.
Clin Pharmacokinet
; 44(5): 467-94, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-15871634
19.
Effect of impaired renal function and haemodialysis on the pharmacokinetics of aprepitant.
Clin Pharmacokinet
; 44(6): 637-47, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-15910011
20.
Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans.
J Clin Pharmacol
; 44(9): 1054-62, 2004 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-15317833